European Commission has approved Braftovi in combination with Mektovi for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. This approval is applicable to all 28 European Union member states, as well as Liechtenstein, Iceland and Norway.
As a science journalist living in the epicenter of the measles outbreak, I did what any reporter would do when I was assigned this story—I texted my medical friends.
